Pharmacological Treatment for Stage C HFp EF (see Table 17)
ÎÎSystolic and diastolic blood pressure should be controlled in patients
with HFpEF in accordance with published clinical practice guidelines
to prevent morbidity. (I-B)
ÎÎDiuretics should be used for relief of symptoms due to volume
overload in patients with HFpEF. (I-C)
ÎÎCoronary revascularization is reasonable in patients with CAD in whom
symptoms (angina) or demonstrable myocardial ischemia is judged
to be having an adverse effect on symptomatic HFpEF despite GDMT.
(IIa-C)
ÎÎManagement of AF according to published clinical practice guidelines
in patients with HFpEF is reasonable to improve symptomatic HF (see
"Important Comorbidities in HF"). (IIa-C)
ÎÎThe use of beta-blocking agents, ACE inhibitors, and ARBs in patients
with hypertension is reasonable to control blood pressure in patients
with HFpEF. (IIa-C)
ÎÎThe use of ARBs might be considered to decrease hospitalizations for
patients with HFpEF. (IIb-B)
ÎÎRoutine use of nutritional supplements is NOT recommended for
patients with HFpEF. (III-C: No Benefit)
Table 17. Recommendations for Treatment of HFpEF
Recommendations
Systolic and diastolic blood pressure should be controlled
according to published clinical practice guidelines
Diuretics should be used for relief of symptoms due to
volume overload
Coronary revascularization for patients with CAD in
whom angina or demonstrable myocardial ischemia is
present despite GDMT
Management of AF according to published clinical practice
guidelines for HFpEF to improve symptomatic HF
Use of beta-blocking agents, ACE inhibitors, and ARBs for
hypertension in HFpEF
ARBs might be considered to decrease hospitalizations in
HFpEF
Nutritional supplementation is NOT recommended in
HFpEF
COR
LOE
I
B
I
C
IIa
C
IIa
C
IIa
C
IIb
B
III: No
Benefit
C
27
